Transcripts - Webcast: https://player.vimeo.com/video/833811575?badge=0&autopause=0&player_id=0&app_id=58479%22 Participants William Doyle, Executive Chairman Ticiana Leal, Emory University Corey J Langer, University of Pennsylvania Pritesh Shah, Chief Growth Officer Ashley Cordova, Chief … Continue Reading
Read nowTranscripts - Webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=VEzQVRmI Participants Frank Bedu-Addo, Chief Executive Officer Lauren V. Wood, Chief Medical Officer Matt Hill, Chief Financial Officer Frank Bedu-Addo, Chief Executive OfficerThanks for … Continue Reading
Read nowTranscripts - Webcast: https://edge.media-server.com/mmc/p/wwuf7739 Presentation: https://ir.dayonebio.com/static-files/0caee55f-c481-48c7-9571-067e51543954 Call Participants: Joey Perrone, Senior Vice President of Finance and Investor Relations Jeremy Bender, Chief Executive Officer Samuel Blackman, Co-Founder and … Continue Reading
Read nowInsights - Eli Lilly (LLY) lifted the bio market yesterday after their amyloid targeting therapy, donanemab, showed that it slowed cognitive and functional decline in a Phase … Continue Reading
PremiumResearch - In mid-March 2023, Pfizer acquired Seagen (SGEN) for $43B, making it the largest biopharma transaction in three years. Seagen, considered the leader in antibody-drug conjugate … Continue Reading
Read nowInsights - In mid-March, Novartis’ combination Tafinlar (dabrafenib) + Mekinist (trametinib) received FDAapproval for pediatric patients with low-grade glioma (pLGG) with a BRAF V600E mutation, the most … Continue Reading
PremiumInsights - Day One’s Drug Ready for NDADay One Pharma (DAWN) is developing tovorafenib (DAY101), an oral pan-RAF inhibitor for pediatric low-grade gliomas (pLGG). Despite being the … Continue Reading
Premium
